- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01206608
Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty
A Randomized, Double-Blind, Active-Control Study to Evaluate the Safety and Efficacy of a Single Local Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Augmentation Mammoplasty
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
This was a Phase 2, parallel-group, active-control, randomized, double-blind study conducted to evaluate a single local administration of low dose or high dose of SKY0402 compared with 75 mg of bupivacaine HCl (i.e., Marcaine® 0.5%) in women undergoing bilateral, cosmetic, sub-muscular, augmentation mammoplasty under general anesthesia. Each subject was to serve as her own control.
A total of 40 subjects were randomized in a 1:1 ratio to receive one of the following regimens:
- Low-dose SKY0402 in one side and Marcaine 75 mg in the contralateral side.
- Mid-dose SKY0402 in one side and Marcaine 75 mg in the contralateral side.
Study drug was administered locally into the breast implant pocket at the end of surgery. After surgery, subjects were to receive standard treatment with acetaminophen 1000 mg three times daily and rescue analgesia with immediate-release oxycodone, as needed, for breakthrough pain.
Assessments of postoperative pain were conducted through 96 hours. Safety assessments were conducted including monitoring of local and systemic adverse events (AEs).
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
California
-
La Jolla, California, Stany Zjednoczone, 92037
- Associates for Plastic Surgery
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
Subjects who met all of the following criteria were eligible for inclusion in the study:
- Women, 18-40 years of age at the Screening Visit.
- Postmenopausal, surgically sterile, or willing to use an acceptable means of contraception for at least 30 days after surgery including any of the following: hormonal contraceptives (e.g., oral, injectable, implantable starting at least 30 days before study drug administration), effective double-barrier methods (e.g., condoms with spermicide), intrauterine device, lifestyle with a personal choice of abstinence, nonheterosexual lifestyle, or a strictly monogamous relationship with a partner who has had a vasectomy.
- Scheduled to undergo primary, bilateral, sub-muscular, augmentation mammoplasty under general anesthesia.
- American Society of Anesthesiology (ASA) Physical Class 1-3.
- Able and willing to comply with all study visits and procedures.
- Able to speak, read, and understand the language of the ICF, study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.
- Willing and capable of providing written informed consent.
Exclusion Criteria:
Subjects were not eligible for the study if they met any of the following criteria:
- Pregnancy, nursing, or planning to become pregnant during the study or within one month after study drug administration.
- Body weight less than 50 kilograms.
- History of hypersensitivity or idiosyncratic reaction to amide-type local anesthetics or to opioid medication.
- Administration of an investigational product within 30 days or 5 elimination half-lives of such investigational product, whichever was longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
- History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
- Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance.
Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicated an increased vulnerability to study drugs and procedures, and exposed the subject to an unreasonable risk as a result of participating in this clinical trial (e.g., severe hepatic insufficiency, hypotension, heart block, or severely impaired cardiac function).
In addition, the subject was ineligible to receive study drug if she met the following criterion during surgery:
- Any clinically significant event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that might render the subject medically unstable or complicate the subject's postoperative course.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Aktywny komparator: Low-dose SKY0402 + bupivacaine HCl
Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
|
Low-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
|
Aktywny komparator: Mid-dose SKY0402 + bupivacaine HCl
Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
|
Mid-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) and With Activity (NRS-A) Pain Intensity Scores
Ramy czasowe: Through 96 hours postdose
|
Assessments of postoperative pain were conducted through 96 hours and included pain intensity at rest (NRS-R) and with activity (NRS-A).
The prescribed activity was to consist of raising the arm, in full extension at the elbow and wrist, to a position parallel with the axis of the torso.
Pain intensity was scored on an 11-point scale, where 0 = no pain and 10 = worst possible pain.
|
Through 96 hours postdose
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Number of Participants With Adverse Events
Ramy czasowe: Through 30 days postdose
|
Adverse events were monitored through Day 8 and serious adverse events through Day 30.
|
Through 30 days postdose
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Kay Warnott, RN, ACNP, Pacira Pharmaceuticals, Inc
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- SKY0402-C-210
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na SKY0402 + bupivacaine HCl
-
Pacira Pharmaceuticals, IncZakończonyLeczenie bólu pooperacyjnegoStany Zjednoczone
-
Pacira Pharmaceuticals, IncZakończonyBól | Zaburzenia czynności wątrobyPolska
-
Ataturk UniversityNieznanyBól pooperacyjny | Rak jelita grubegoIndyk
-
Pacira Pharmaceuticals, IncZakończony
-
University of California, San DiegoPacira Pharmaceuticals, IncZakończonyZdrowi WolontariuszeStany Zjednoczone
-
InnocollPremier Research Group plcZakończonyBól, pooperacyjnyStany Zjednoczone
-
University of Kansas Medical CenterNational Cancer Institute (NCI)ZakończonyRak piersiStany Zjednoczone
-
DurectZakończonyBól pooperacyjnyStany Zjednoczone
-
Eli Lilly and CompanyZakończonyNiedrobnokomórkowy rak płucStany Zjednoczone